Month: March 2023

Eli Lilly will cut prices for some older insulins later this year and immediately give more patients access to a cap on the costs they pay to fill prescriptions.

The moves announced Wednesday promise critical relief to some people with diabetes who can face thousands of dollars in annual costs for insulin they need in order to live. Lilly’s changes also come as lawmakers and patient advocates pressure drugmakers to do something about soaring prices.

Lilly said it will cut the list prices for its most commonly prescribed insulin, Humalog, and for another insulin, Humulin, by 70% or more in the fourth quarter, which starts in October.

List prices are what a drugmaker initially sets for a product and what people who have no insurance or plans with high deductibles are sometimes stuck paying.

A Lilly spokeswoman said the current list price for a 10-milliliter vial of the fast-acting, mealtime insulin Humalog is $274.70. That will fall to $66.40.

Likewise, she said the same amount of Humulin currently lists at $148.70. That will change to $44.61.

Lilly CEO David Ricks said Wednesday that his company was making the changes to address issues that affect the price patients ultimately pay for its insulins.

He noted that discounts Lilly offers from its list prices often don’t reach patients through insurers or pharmacy benefit managers. High-deductible coverage can lead to big bills at the pharmacy counter, particularly at the start of the year when the deductibles renew.

“We know the current U.S. health care system has gaps,” he said. “This makes a tough disease like diabetes even harder to manage.”

Patient advocates have long called for insulin price cuts to help uninsured people who would not be affected by price caps tied to insurance coverage.

Lilly’s planned cuts “could actually provide some substantial price relief,” said Stacie Dusetzina, a health policy professor at Vanderbilt University who studies drug costs.

She noted that the moves likely won’t affect Lilly much financially because the insulins are older, and some already face competition.

Lilly also said Wednesday that it will cut the price of its authorized generic version of Humalog to $25 a vial starting in May.

Lilly also is launching in April a biosimilar insulin to compete with Sanofi’s Lantus.

Ricks said that it will take time for insurers and the pharmacy system to implement its price cuts, so the drugmaker will immediately cap monthly out-of-pocket costs at $35 for people who are not covered by Medicare’s prescription drug program.

The drugmaker said the cap applies to people with commercial coverage and at most retail pharmacies.

Lilly said people without insurance can find savings cards to receive insulin for the same amount at its InsulinAffordability.com website.

The federal government in January started applying that cap to patients with coverage through its Medicare program for people 65 and older or those who have certain disabilities or illnesses.

President Joe Biden brought up that cost cap during his annual State of the Union address last month. He called for insulin costs for everyone to be capped at $35.

Biden said in a statement Wednesday that Lilly responded to his call.

“It’s a big deal, and it’s time for other manufacturers to follow,” Biden said.

Aside from Eli Lilly and the French drugmaker Sanofi, other insulin makers include the Danish pharmaceutical company Novo Nordisk.

Representatives for both Sanofi and Novo Nordisk said their companies offer several programs that limit costs for people with and without coverage.

Source: Voice of America

NASA’s DART spacecraft slammed into the asteroid Dimorphos at a spot between two boulders during last September’s first test of a planetary defense system, sending debris hurtling into space and changing the rocky, oblong-shaped object’s path a bit more than previously calculated.

Those were among the findings released by scientists on Wednesday in the most detailed account of the U.S. space agency’s proof-of-principle mission on using a spacecraft to change a celestial object’s trajectory — employing sheer kinetic force to nudge it off course just enough to keep Earth safe.

“The DART test was phenomenally successful. We now know that we have a viable technique for potentially preventing an asteroid impact if one day we had the need to,” said planetary scientist Terik Daly of the Johns Hopkins University Applied Physics Laboratory in Maryland, lead author of one of the DART studies published in the journal Nature.

The Double Asteroid Redirection Test (DART) spacecraft collided on September 26, 2022, at 22,530 kilometers per hour with Dimorphos, an asteroid about 150 meters in diameter, roughly 11 million kilometers from Earth. Dimorphos is a moonlet of Didymos, which is defined as a near-Earth asteroid and has a shape like a top spinning in space with a diameter of about 780 meters. Neither object imperils Earth.

“We were trying to change the amount of time that it took for Dimorphos to orbit around Didymos by colliding head-on with Dimorphos,” said Northern Arizona University planetary scientist Cristina Thomas, lead author of another of the studies published in Nature.

“The momentum of the collision and the momentum of the ejected material both acted to decrease the amount of time it takes Dimorphos to orbit by 33 minutes. This also results in the object orbiting a little bit closer to Didymos,” Thomas said.

Before the impact, the orbital period was 11 hours, 55 minutes. It now is 11 hours, 22 minutes. NASA’s previous estimate, announced in October, was an orbital change of 32 minutes. The benchmark for success had been set as a change of at least 1 minute, 13 seconds.

The scientists gave a blow-by-blow account of how the collision unfolded.

“First, one of the spacecraft’s solar panels directly hit a large boulder near the impact site. Next, the second solar panel grazed another large boulder. Finally, the spacecraft bus — the box between the solar panels — hit between these two boulders,” Daly said.

“We suspect that these two boulders were destroyed. After impact, ejecta [debris blasted into space] was launched from the surface for a period of time,” Daly added, saying satellite and telescope images showed a large amount of such material.

The research also clarified details such as the precise location of the impact and the angle of impact.

“People may think of the DART mission as a fairly straightforward experiment that is similar to playing billiards in space — one solid spacecraft impacts into one solid asteroid,” Thomas said. “However, asteroids are far more complex than just a solid rock. In fact, most asteroids are what we think of as rubble piles.”

The $330 million DART mission was seven years in development.

“We don’t know of any asteroids at this time that pose a threat to Earth, but we want to be ready for such a scenario,” Daly said. “It’s analogous to testing a car’s airbags. You make sure they work during a crash test instead of waiting to get in a real car accident to find out if they work.”

Source: Voice of America